Filed on behalf of Patent Owners Genentech, Inc. and City of Hope by:
`
`David L. Cavanaugh
`Reg. No. 36,476
`Owen K. Allen
`Reg. No. 71,118
`Heather M. Petruzzi
`Reg. No. 71,270
`Robert J. Gunther, Jr.
`Pro Hac Vice
`Wilmer Cutler Pickering
`Hale and Dorr LLP
`1875 Pennsylvania Ave., NW
`Washington, DC 20006
`
`
`Adam R. Brausa
`Reg. No. 60,287
`Daralyn J. Durie
`Pro Hac Vice
`Durie Tangri LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`
`Michael R. Fleming
`Reg. No. 67,933
`David I. Gindler
`Pro Hac Vice
`Joseph M. Lipner
`Pro Hac Vice
`Irell & Manella LLP
`1800 Avenue of the
`Stars, Suite 900
`Los Angeles, CA
`90067
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________________________
`
`MYLAN PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`GENENTECH, INC. AND CITY OF HOPE,
`Patent Owners.
`____________________________________________
`
`Case IPR2016-00710
`Patent 6,331,415
`____________________________________________
`
`PATENT OWNERS’ MOTION TO SEAL
`
`
`
`
`
`David L. Cavanaugh
`Reg. No. 36,476
`Owen K. Allen
`Reg. No. 71,118
`Heather M. Petruzzi
`Reg. No. 71,270
`Robert J. Gunther, Jr.
`Pro Hac Vice
`Wilmer Cutler Pickering
`Hale and Dorr LLP
`1875 Pennsylvania Ave., NW
`Washington, DC 20006
`
`
`Adam R. Brausa
`Reg. No. 60,287
`Daralyn J. Durie
`Pro Hac Vice
`Durie Tangri LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`
`Michael R. Fleming
`Reg. No. 67,933
`David I. Gindler
`Pro Hac Vice
`Joseph M. Lipner
`Pro Hac Vice
`Irell & Manella LLP
`1800 Avenue of the
`Stars, Suite 900
`Los Angeles, CA
`90067
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________________________
`
`MYLAN PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`GENENTECH, INC. AND CITY OF HOPE,
`Patent Owners.
`____________________________________________
`
`Case IPR2016-00710
`Patent 6,331,415
`____________________________________________
`
`PATENT OWNERS’ MOTION TO SEAL
`
`
`
`
`
`STATEMENT OF PRECISE RELIEF REQUESTED
`
`IPR2016-00710
`Patent Owners’ Motion to Seal
`
`
`Pursuant to 37 C.F.R. §§ 42.14 and 42.54, Petitioners Genentech, Inc. and
`
`City of Hope respectfully request that the Board seal Exhibits 2033 (Declaration of
`
`Julie L. Davis), 2090 (Deposition Transcript of James H. Sabry, M.D.), 2091
`
`(Deposition Transcript of Timothy R. Schwartz), 2093 (Expert Report of Robert C.
`
`Rickert, Ph.D.), 2111 (Exhibit 17 to Deposition of Timothy R. Schwartz), 2114-
`
`2118 (Appendices A-E to Declaration of Julie L. Davis), 2130 (Compilation of
`
`License Agreements), 2131 (Compilation of Settlement Agreements), 2132
`
`(Compilation of Royalty Statements), 2136 (Summary of Genentech Licensing
`
`Agreements), and 2137 (Selected Historical Financial Data).
`
`REASONS FOR RELIEF REQUESTED
`
`
`
`Although “the default rule is that all papers filed in an inter partes review
`
`are open and available for access by the public,” a party may file a motion with the
`
`Board to seal confidential information that is protected from disclosure. Garmin v.
`
`Cuozzo, IPR2012-00001, Paper No. 36. “The standard for granting a motion to
`
`seal is ‘for good cause.’” Id. (quoting 37 C.F.R § 42.54). The Office Patent Trial
`
`Practice Guide, 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012), states that the “rules
`
`identify confidential information in a manner consistent with Federal Rule of Civil
`
`Procedure (“FRCP”) 26(c)(1)(G), which provides for protective orders for trade
`
`secret or other confidential research, development, or commercial information.”
`
`
`
`1
`
`
`
`The parties have conferred and agreed to the provisions of the Modified
`
`IPR2016-00710
`Patent Owners’ Motion to Seal
`
`
`Default Standing Protective Order set forth in Exhibit 2098, and have stipulated to
`
`be bound to the terms set forth therein. Exhibit 2099 shows the proposed
`
`modifications from the Default Standing Protective Order in redline. The
`
`Modified Default Standing Protective Order provides:
`
`Where confidentiality is alleged as to some but not all of the
`information submitted to the Board, the submitting party shall file
`confidential and non-confidential versions of its submission, together
`with a Motion to Seal the confidential version setting forth the reasons
`why the information redacted from the non-confidential version is
`confidential and should not be made available to the public. The
`nonconfidential version of the submission shall clearly indicate the
`locations of information that has been redacted. The confidential
`version of the submission shall be filed under seal. The redacted
`information shall remain under seal unless, upon motion of a party
`and after a hearing on the issue, or sua sponte, the Board determines
`that some or all of the redacted information does not qualify for
`confidential treatment.
`(Ex. 2098, Modified Default Standing Protective Order at 3.)
`
`Exhibit 2033 is a declaration regarding secondary considerations by Patent
`
`Owners’ expert Julie L. Davis. The redacted portions of Exhibit 2033 contain
`
`information pertaining to confidential royalty statements and licensing and
`
`
`
`2
`
`
`
`settlement terms with Patent Owners’ competitors, and are therefore “confidential
`
`IPR2016-00710
`Patent Owners’ Motion to Seal
`
`
`… commercial information” pursuant to FRCP 26(c)(1)(G).
`
`Exhibits 2114-2118 are Appendices A-E to the Declaration of Julie L. Davis
`
`(Exhibit 2033, discussed supra). Exhibit 2114 (Appendix A) is a summary of
`
`confidential license agreements pertaining to U.S. Patent No. 6,331,415. Exhibit
`
`2115 (Appendix B) is a summary of confidential settlement agreements pertaining
`
`to U.S. Patent No. 6,331,415. Exhibit 2116 (Appendix C) is a summary of sales of
`
`Genentech’s products pertaining to U.S. Patent No. 6,331,415, which is
`
`confidential proprietary company information. Exhibit 2117 (Appendix D) is a
`
`summary of licensee sales and royalties paid to Genentech pertaining to U.S.
`
`Patent No. 6,331,415, which is confidential proprietary company information.
`
`Exhibit 2118 (Appendix E) contains confidential commercial information related
`
`to royalties paid to Genentech pertaining to U.S. Patent No. 6,331,415.
`
`Accordingly, Exhibits 2114-2118 are “confidential … commercial information”
`
`pursuant to FRCP 26(c)(1)(G).
`
`Exhibit 2130 is a compilation of license agreements involving U.S. Patent
`
`No. 6,331,415. The terms of these license agreements are confidential. The
`
`contents of this exhibit therefore constitute “confidential … commercial
`
`information” pursuant to FRCP 26(c)(1)(G).
`
`
`
`3
`
`
`
`Exhibit 2131 is a compilation of settlement agreements involving U.S.
`
`IPR2016-00710
`Patent Owners’ Motion to Seal
`
`
`Patent No. 6,331,415. The terms of these settlement agreements are confidential.
`
`The contents of this exhibit therefore constitute “confidential … commercial
`
`information” pursuant to FRCP 26(c)(1)(G).
`
`Exhibit 2132 is a compilation of royalty statements involving U.S. Patent
`
`No. 6,331,415. These royalty statements are confidential. The contents of this
`
`exhibit therefore constitute “confidential … commercial information” pursuant to
`
`FRCP 26(c)(1)(G).
`
`Exhibit 2136 is a summary of Genentech’s licensing agreements involving
`
`U.S. Patent No. 6,331,415. The terms of these licensing agreements are
`
`confidential. The contents of this exhibit therefore constitute “confidential …
`
`commercial information” pursuant to FRCP 26(c)(1)(G).Exhibits 2090 and 2091
`
`are deposition transcripts of James H. Sabry, M.D., and Timothy R. Schwartz,
`
`respectively, from the district court litigation titled Sanofi-Aventis U.S. LLC v.
`
`Genentech, Inc., No. 15-cv-05685 (C.D. Cal.). Exhibits 2090 and 2091 contain
`
`testimony concerning confidential and sensitive information regarding how
`
`Genentech’s products are made. Exhibit 2091 was further marked as “Attorneys’
`
`Eyes Only” in the litigation.
`
`Exhibit 2093 is an expert report of Robert C. Rickert, Ph.D. from the district
`
`court litigation titled Bristol-Myers Squibb Co. v. Genentech, Inc., No. 13-cv-
`
`
`
`4
`
`
`
`07248-MRP-JEM (C.D. Cal.). Exhibit 2093 contains confidential and sensitive
`
`IPR2016-00710
`Patent Owners’ Motion to Seal
`
`
`information regarding how Genentech’s products are made. Furthermore, this
`
`report was marked as “Confidential” in the litigation.
`
`Exhibits 2111 and 2137 describe confidential selected historical financial
`
`data for several of Genentech’s products that are not otherwise available in
`
`publicly accessible sources. These financial data constitute “confidential …
`
`commercial information” pursuant to FRCP 26(c)(1)(G).
`
`Patent Owners therefore respectfully requests that the aforementioned
`
`materials remain under seal pursuant to the Proposed Modified Default Standing
`
`Protective Order.
`
`Respectfully submitted,
`
`/David L. Cavanaugh/
`
`David L. Cavanaugh
`Registration No. 36,476
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`1875 Pennsylvania Avenue, N.W.
`Washington, D.C. 20006
`david.cavanaugh@wilmerhale.com
`Tel.: 202-663-6000
`Fax: 202-663-6363
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: December 22, 2016
`
`
`
`5
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
